Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 37 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
MEDPACE LABORATORIES from Leuven, company number BE0879502859, closed financial year 2025 with a result of € 1.4 million after tax. For that financial year MEDPACE LABORATORIES recorded revenue of € 58.2 million and equity of € 17.1 million. Compared with financial year 2024, the result moved from € 1.5 million to € 1.4 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
€ 17.1 million
▲ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.4 million
▼ 2% vs 2024
Profit after tax over the fiscal year.
€ 218,109
▼ 85% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 8.9 million.
People and assets in 2025
156.5
▼ 3.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 12.3 million
▲ 6% vs 2024
€ 78,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 179,519
▼ 32% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 4.6 million
▲ 19% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 39 days on average.
€ 2.3 million
▲ 17% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 48,700,214 | € 57,567,115 | € 57,117,222 | € 58,172,572 | ▲ 2% |
| Profit after taxes | € 974,995 | € 1,626,436 | € 1,464,819 | € 1,434,830 | ▼ 2% |
| Equity | € 8,370,527 | € 14,196,964 | € 15,661,783 | € 17,096,613 | ▲ 9% |
| Total debts | € 11,234,644 | € 14,879,792 | € 10,844,480 | € 8,453,947 | ▼ 22% |
| Cash | € 108,491 | € 5,047,631 | € 1,477,468 | € 218,109 | ▼ 85% |
| Land & buildings | € 7,165,743 | € 11,360,449 | € 10,485,823 | € 11,945,523 | ▲ 14% |
| Retained profit | € 4,370,527 | € 5,996,964 | € 7,461,783 | € 8,896,613 | ▲ 19% |
| Balance sheet total | € 19,605,171 | € 29,076,756 | € 26,595,124 | € 25,550,559 | ▼ 4% |
| Employees (FTE) | 136.9 | 160.9 | 160.4 | 156.5 | ▼ 3.9 |
Key figures of MEDPACE LABORATORIES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDPACE LABORATORIES?
What happened at MEDPACE LABORATORIES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1.4 million (▼ 2% vs 2024). Source: NBB ↗
- John Thomas Wynne II became a director. NBB
- Brad William Hansman became a director. NBB
- Kevin Michael Brady became a director. NBB
- Jesse Jacob Geiger stepped down as director. NBB
- Stephen Paul Ewald became a director. NBB
- Jesse Jacob Geiger became a director. NBB
- New establishment in Leuven. KBO
In short
From € 974,995 profit in 2022 to € 1.4 million profit in 2025.
Paid € 1.7 million in corporate taxes since 2022.
Best year ever: 2023, with € 1.6 million profit.
Pays suppliers within 39 days on average.
A new publication or filing at MEDPACE LABORATORIES? We notify you, reason included.
Follow MEDPACE LABORATORIESDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind MEDPACE LABORATORIES are Stephen Paul Ewald, John Thomas Wynne II, Brad William Hansman and Kevin Michael Brady. The shares are held by LLC Medpace Reference Laboratories (100%).
Directors
According to the 2025 annual accounts
Stephen Paul Ewald
Director
since 2021
John Thomas Wynne II
Director
since 2026
Brad William Hansman
Director
since 2026
Kevin Michael Brady
Director
since 2026
Jesse Jacob Geiger
Director
since 2021 · until 2026
Shareholders
LLC Medpace Reference Laboratories
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Technologielaan 19
3001 Leuven
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0879.502.859
- VAT number
- BE 0879.502.859
- Registered office
- Technologielaan 19, 3001 Leuven
- Names & denominations
- MEDPACE LABORATORIES
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 20 February 2006
- Peppol
- Active · Active since 22 Dec 2025
- Activities · NACE
Activiteiten van medische beeldvorming en medische laboratoria
Medische laboratoria
Activiteiten van medische laboratoria